This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ4F0NP_L.jpg
(Reuters) – Commissioners at the U.S. Federal Trade Commission (FTC) have not yet met to discuss Amgen (NASDAQ:AMGN)’s acquisition of Horizon Therapeutics (NASDAQ:HZNP), CNBC reported on Tuesday.
The news comes a day after reports that the FTC is expected to file a lawsuit as early as Tuesday to block the $27.8 billion deal.
